Calgary, Canada (ots/PRNewswire) - Resverlogix Corp.
("Resverlogix" or the "Company") announces that Mr. Kenneth Zuerblis
has been appointed to the Company's Board of Directors. Recently Mr.
Zuerblis served as the Chief Financial Officer and Senior Vice
President of ImClone Systems Inc., prior to its acquisition by Eli
"I was initially attracted to Resverlogix because of RVX-208, its
novel atherosclerosis drug, which is a very exciting mid-stage
therapeutic gaining worldwide scientific acceptance. Resverlogix is
also developing a pipeline of novel therapeutics in several disease
categories that have significant unmet medical needs. I look forward
to this opportunity to work with members of the Board of Directors
and management as we develop the full potential of the Company's
product candidates," Mr. Zuerblis commented.
Donald J. McCaffrey, President & CEO of Resverlogix, stated, "Ken
is a seasoned veteran in the biotechnology industry with a proven
track record of running complex commercial and research organizations
and we are delighted that he has joined our Board of Directors." In
an effort to maintain a Board of Director level at six people Mr.
Wayne Chiu will be stepping down from the Board effective today.
Wayne has been on the Board since its inception and has been an
important contributor to the growth and development of Resverlogix.
The Board expresses its thankfulness to Wayne for his years of
Kenneth J. Zuerblis biography
Mr. Zuerblis previously served as Chief Financial Officer and
Senior Vice President of ImClone Systems, a biopharmaceutical company
developing biologic medicines in the area of oncology, from 2008
through 2009 at which time he helped lead the sale of the company to
Eli Lilly for $6.6 billion USD. Prior to joining ImClone, Mr.
Zuerblis served as Chief Financial Officer of Enzon Pharmaceuticals
Inc. from 1994 through 2005 and Corporate Controller from 1991
through 1994. He began his career at KPMG, LLP, in 1982, ultimately
serving as Senior Manager prior to his departure in 1991. Mr.
Zuerblis previously served as a member of the Board of Directors of
XTL Biopharmaceuticals, Ltd., and is a member of the Board of
Directors of Immunomedics and the New Jersey Technology Council. He
received a BS in Accounting from Seton Hall University and is a
certified public accountant in the State of New Jersey.
About Resverlogix Corp.
Resverlogix Corp. is a leading biotechnology company engaged in
the development of novel therapies for important global medical
markets with significant unmet medical needs. The NexVas(TM) PR
program is the Company's primary focus which is to develop novel
small molecules that enhance ApoA-1. These vital therapies address
the burden of atherosclerosis and other important diseases such as
Acute Coronary Syndrome, Diabetes, Alzheimer's disease, Peripheral
Artery Disease and other vascular disorders. Resverlogix Corp.'s
common shares trade on the Toronto Stock Exchange . For further
information please visit http://www.resverlogix.com.
This news release may contain certain forward-looking statements
as defined under applicable Canadian securities legislation,
including our statements with respect to research, development and
commercialization of novel therapeutics that reduce the risk of
cardiovascular disease including atherosclerosis, diabetes,
Alzheimer's disease, Peripheral Artery Disease and other vascular
diseases. These forward-looking statements contained herein that are
not based on historical fact, including without limitation statements
containing the words "believes", "anticipates", "plans", "intends",
"will", "should", "expects", "continue", "estimate", "forecasts" and
other similar expressions. Our actual results, events or developments
could be materially different from those expressed or implied by
these forward-looking statements. We can give no assurance that any
of the events or expectations will occur or be realized. By their
nature, forward-looking statements are subject to numerous known and
unknown risks and uncertainties including but not limited to those
associated with the success of research and development programs,
clinical trial programs including possible delays in patient
recruitment, the regulatory approval process, competition, securing
and maintaining corporate alliances, market acceptance of the
Company's products, the availability of government and insurance
reimbursements for the Company's products, the strength of
intellectual property, financing capability, the potential dilutive
effects of any financing, reliance on subcontractors and key
personnel and additional risk factors discussed in other documents we
file from time to time with securities authorities, which are
available through SEDAR at http://www.sedar.com. Additionally, risks
and uncertainties are discussed in detail in the July 31, 2010 MD&A.
The forward-looking statements contained in this news release are
expressly qualified by this cautionary statement are made as of the
date hereof. The Company disclaims any intention and has no
obligation or responsibility, except as required by law, to update or
revise any forward-looking statements, whether as a result of new
information, future events or otherwise. The TSX Exchange does not
accept responsibility for the adequacy or accuracy of this news
For further information: Theresa Kennedy, VP, Corporate
Communications, Resverlogix Corp., Phone: +1-403-254-9252, Email:
Theresa@resverlogix.com; US Institutional Investors: Susan Noonan,
Managing Partner, S.A. Noonan Communications, LLC, Phone:
+1-212-966-3650, Email: Susan@sanoonan.com
ots Originaltext: Resverlogix Corp.
Im Internet recherchierbar: http://www.presseportal.ch
CONTACT: For further information: Theresa Kennedy, VP,
CorporateCommunications, Resverlogix Corp., Phone: +1-403-254-9252,
Email:Theresa@resverlogix.com; US Institutional Investors: Susan
Noonan, ManagingPartner, S.A. Noonan Communications, LLC, Phone: